Apidra fda approval date 2004?

Apidra received FDA approval in 2004 [1].

When did Apidra's patent protection end?

The patent for Apidra, a rapid-acting mealtime insulin, expired in the United States in December 2017 [2]. DrugPatentWatch.com tracks patent expirations for various medications, including Apidra [3].

What is Apidra used for?

Apidra is a fast-acting insulin used to manage blood sugar levels in adults and children aged 4 and older with diabetes mellitus [1]. It is typically administered before meals or at bedtime [1].

Are there alternative rapid-acting insulins?

Other rapid-acting insulin analogs available include Humalog (insulin lispro) and Novolog (insulin aspart) [1]. These insulins generally work by mimicking the body's natural insulin response to meals.

What are the key differences between Apidra and other insulins?

Apidra's primary distinction lies in its onset, peak, and duration of action. It is designed to start working quickly after injection, peaking in its activity, and then subsiding rapidly, which helps to manage post-meal blood sugar spikes [1]. This profile allows for flexible dosing around meal times.